Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Novo Nordisk and Eli Lilly, the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, analysts say.